A Live Attenuated Vaccine for Prevention and Control of Aeromonas Haemorrhagic Disease in Aquaculture Animals

Abstract

The invention discloses an attenuated live vaccine for preventing and controlling Aeromonas haemorrhagic disease of aquaculture animals. The invention provides a recombinant bacterium, which is obtained by knocking out the aerolysin gene in Aeromonas vernerii. The recombinant bacterium can be used to prepare the Aeromonas victoria vaccine and / or the Aeromonas hydrophila vaccine and / or the Aeromonas vaccine and / or the haemorrhagic disease vaccine for aquatic animals. The oral or bath attenuated live vaccine constructed by the present invention using the technology of knocking out key virulence factors without antibiotic markers can reduce the pathogenicity of pathogenic bacteria while retaining immune antigenicity, has a significant immune protection effect, and enhances the natural immune system response and cell Immunity, enhance the ability to resist other pathogenic bacteria infection, while greatly reducing the workload of immunity.

Description

technical field [0001] The invention relates to an attenuated live vaccine for preventing and controlling Aeromonas hemorrhagic disease of aquaculture animals. Background technique [0002] China is the largest aquaculture producing country in the world, accounting for more than 60% of the world's aquaculture production. With the increasing intensification and commercialization of aquaculture production practices, disease outbreaks have become a major problem in the fish farming industry. In particular, fish hemorrhagic disease caused by Aeromonas has become a very prominent problem in the development of aquaculture. Fish disease outbreaks are estimated to cost the global aquaculture industry an estimated billions of dollars annually. For example, outbreaks of motile Aeromonas sepsis (MAS), caused by Aeromonas spp., often lead to high fish mortality and severe economic losses in aquaculture worldwide. Over the past few decades, antibiotics have been used as a traditional ...

AI Technical Summary

Problems solved by technology

[0003] At present, the vaccine prevention and treatment of bacterial sepsis is mainly focused on the development of vaccines for the infectious bacteria Aeromonas hydrophila that enters after the destruction of the intestinal / gill barrier due to the unknown pathogenic mechanism in the early stage. There are few reports on the development of vaccines against the key bacterium Aeromonas versicolor for host physical barriers, mainly including traditional inactivated vaccines of highly virulent strains, in addition to reports of Aeromonas veroris sloughs and the introduction of specific aptamers Peptide Aeromonas victoria vaccines, most of which are immunized by injection, have the following defects: 1) The inactivation process leads to partial or complete loss of protective antigens, which can only cause unstable or low-level immune responses , can not even stimulate the correct immune response and cause side effects, etc.; 2) the production yield of Aeromonas verdeii slough is low, and the cleavage gene has the disadvantages of toxicity; 3) The specific aptamer peptide of the Aeromonas Avoid the shortcomings of self-virulence gene expression causing disease, 4) Fish injection immunization has the disadvantage of heavy workload

Images